Chang Yi Wang; simplified Chinese: 王长怡) is the founder of United Biomedical, Inc. (UBI) , headquartered in Hauppauge, New York, and its group of companies in Asia, including United BioPharma (UBP) a spinoff company from UBI-Asia. Dr. Wang has served as chief scientific officer of UBI since its inception in December 1985, and as chairperson and chief executive officer of the UBI Group of companies since 1998. Dr. Wang is the author of more than 120 peer-reviewed scientific publications including a New England Journal of Medicine article describing monotherapy with UB-421 which blocks the HIV virus-binding site on human CD4-T-cells and maintains viral suppression for up to 16 weeks in HIV-infected persons undergoing analytical treatment interruption. UB421 is Dr. Wang’s invention, stemming from the original finding of a class of CD4 targeting antibodies having competitive HIV binding inhibition properties and associated functional characteristics. With CD4 being an important immune modulatory molecule, this finding has led to numerous important first-in-human clinical applications. Dr. Wang is the inventor of more than 100 patents to date. She has given various keynote and plenary lectures both nationally and internationally in the areas of Immunology, vaccination, immunotherapeutics and Infectious disease. She has also served on the scientific review committee for the Cooperative Research Partnerships for BioDefense and Allergy and Immunobiology programs funded and administered by the U.S. National Institutes of Health (NIH) . In 2007, the New York Intellectual Property Law Association ( NYIPLA) presented Dr. Wang with the Inventor of the Year Award. In 2018, the Brain Mapping Foundation presented Dr. Wang with the Pioneer in Technology Award for her contribution in the development of therapeutic vaccines for the treatment of Neurodegenerative Diseases. In early 2020 during the surprising closing of the WuHan city due to the outbreak of SARS-CoV2, Dr. Wang, determined to utilize her expertise accumulated over the decades in designing viral sequence based innovative antibody screening diagnostics and vaccine, led the UBI group of companies once again in our fight against this disastrous COVID 19 global pandemic with its first product UBI SARS-CoV-2 ELISA for antibody screening received US FDA EUA approval in 2021; and a second product UB-612, A Multitope Universal Vaccine against SARS-CoV-2 Variants of Concern (VoCs), which is safe and provides broad and long lasting B- and T cell immune responses, soon to receive EUAs from two countries for global use.
The booster-enhanced broadly-neutralizing and durable antibodies along with robust T-cell immunity by UB-612, a multitope vaccine which contains S1-RBD-sFc fusion protein enriched with five rationally-designed promiscuous peptides representing conserved Th and CTL epitopes on the Sarbecovirus N, M and S2 proteins across all VoCs allows not only for control of Omicrons or ever-emergent new strains, but also provides another subunit vaccine platform to fend of other infectious viral agents for previously unfinished wars against HIV and Hepatitis B.
Early life and education
Dr. Wang was born in Taipei, Taiwan. She attended the prestigious Taipei First Girls' High School, where she first became aware of the double helix structure of DNA, which served as one of the primary motivators for her lifetime pursuit of biomedical sciences. She graduated with honor from National Taiwan University in 1973, majoring in chemistry. Dr. Wang was the first Asian woman accepted into the graduate program at Rockefeller University in the United States, where in 1979 she received a Ph.D. degree with dual specialization in Biochemistry and Immunology. She joined the Memorial Sloan Kettering Cancer Center from 1979 to 1985, becoming its youngest faculty member, principal investigator and head of the molecular immunology laboratory, endowed by the Arthur J. and Leslie Levine Fund.
Career in immunology and entrepreneurship in the biomedical industry
Dr. Wang has been a pioneer in advocating “immunology as a secret weapon in medicine,” combined with personal motivation for developing medical interventions via application of basic biomedical sciences. Her first such achievements in terms of immunological applications of synthetic peptides were antibody screening immunoassays employing highly optimized synthetic viral peptide antigens. The first involved developing a synthetic peptide-based HIV 1, and later an HIV 1,2 diagnostic test for blood screening, both of which received U.S. Food and Drug Administration approval, in 1989 and 1996, respectively. These tests were subsequently recognized by the WHO as being suitable for worldwide use. Her other contributions in this area include synthetic peptide-based blood screening diagnostics for HTLV I/II and the Hepatitis C virus (HCV), which received CE certification and was sold in the global market through Organon Teknika /Biomerieux since 1991, as well as screening diagnostics for the SARS coronavirus, and diagnostic tests for the differentiation of infected vs. vaccinated animals for foot and mouth disease.
Since 1992, she has received support and guidance from Nobel laureate Dr. James D. Watson, the co-discoverer of the double-helix DNA structure and a board member of United Biomedical, Inc at the time, in the courageous pursuit of many challenging vaccine and immunotherapy programs employing designer synthetic peptides.
At the invitation of the Taiwanese government in 1998, (Ministry of Economic Affairs and National Development Fund), Dr. Wang, , set out to establish UBI-Asia as a joint venture with between United Biomedical, Inc. (UBI) based in the US and the Taiwan governments. Upon establishing UBI Asia in Taiwan in 1999, Dr. Wang’s mission was to position UBI Asia as the center of excellence in the protein and monoclonal antibody drug-development area. In line with her mission, she launched a state-of-the-art protein and antibody drug development platform within UBI Asia, employing monoclonal antibody B4 as a touch stone and built a competent team with integrated platform technologies to enable development of antibody products from DNA to BLA filings. Other antibody and long acting protein products followed, leading to the spinoff of United Biopharma with a group of rigorously selected antibody products. She assembled and led a team of scientists and industrial experts to ensure the establishment of an integrated platform technology and a rich pipeline of high-impact products. The UB421 monoclonal antibody, with a series of issued and pending patents, is in phase III trials for HIV treatment as a HAART substitution, as well as other applications including functional cure. Many other products are currently in various preclinical and clinical stages of development. In order to fully develop and commercialize these products, two companies, United BioPharma and UBI Pharma, were spun off from UBI Asia to allow dedicated resources for commercialization of the respective pipelines of monoclonal antibodies and long-acting protein drugs. The two companies have also established respective state-of-the-art manufacturing facilities at both Hsin Chu, Taiwan and Yangzhou, China to prepare for commercialization of these innovative protein drugs worldwide.
Challenging Chiron’s broad HCV epitope claims and worldwide HCV patents
Dr. Wang’s patent for diagnostic Hepatitis C virus (HCV) peptide epitopes was the first such patent issued in the United States which was also subsequently licensed to Roche Diagnostics. Partnering with distributor Organon Teknika/Biomerieux, UBI’s peptide antigen-based HCV blood-screening test was a success in Europe in the early 1990s. However, patent litigation ensued between Chiron et al. and UBI et al. regarding Chiron’s broadly claimed HCV epitope patent. Six Nobel laureates served as expert witnesses and judicial advisors in the UK court to dispute the validity of the broadly claimed Chiron HCV epitope/peptide patent. Following years of litigation and Dr. Wang’s valiant efforts in putting forth technical arguments challenging the validity of Chiron’s overly broad HCV epitope claims, UBI prevailed. In the year of 2000, the Technical Board of the European Patent Office invalidated all overly broad HCV epitope claims. Meanwhile, the UK’s Section 44 patent law was also repealed at the advice of a team of experts including patent barristers and judges setting a case for “lack of support can be used to attack the breadth of patent claims even after the patent is issued”. This result freed up valuable information derived from detailed RNA or DNA sequences for public research and follow-up inventions, finally allowing for worldwide use of the vast amount of Genomic sequence generated by the biomedical community.
Pioneering high precision designer peptide-based vaccines and immunotherapeutics as a new class of biologicals
For the past 25 years, Dr. Wang has dedicated herself to the discovery, design and development of a new class of biologicals comprising Immunotherapeutics and vaccines for the therapy and prevention of chronic and infectious diseases, and companion diagnostics for monitoring treatment and control of these diseases. The resultant peptide-based biologicals act by directing the immune system to specific functional target sites and have great potential in a wide range of therapeutic areas.
Under her direction, “UBITh”, a new platform technology in high precision peptide immunogen design for the development of innovative vaccines and immunotherapeutics, was established. Some examples include a site-specific UBITh amyloid-β vaccine and Tau vaccine for Alzheimer’s disease, a site-specific Alpha Synuclein vaccine for Parkinson’s disease, an IgE vaccine for allergic diseases, and others for multiple human and animal health applications, including an LHRH vaccine for boar taint removal via immunocastration, and vaccines against infections caused by Porcine circovirus, Porcine Reproductive and Respiratory Syndrome Virus, and Foot and mouth disease viruses. Her high precision peptide based LHRH targeted immunocastration vaccine has also been launched in the global swine market. Validation for the UBITh vaccine technology has been demonstrated by achieving the long-sought goal of producing a Synthetic peptide vaccine for Foot and mouth disease, selling over 3 billion doses since introduction in 2007 in China, the largest swine market. These initial inventions have provided UBI with commercialization expertise to become an industry leader in many high precision peptide vaccine applications in disease intervention as immunotherapeutics.
During her research career in the US, Dr. Wang has received over US$20 million in grants and contracts from national Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) of National Institutes of Health (NIH).
First Asian female recipient of the NYIPLA Inventor of the Year Award
The New York Intellectual Property Law Association’s Inventor of the Year award recognizes an individual or group who, through inventive talents, has made worthwhile contributions to society by promoting “the progress of science and useful arts”. Dr. Chang Yi Wang was the 2007 recipient for her work on “UBITh peptide immunogens”. Dr. Wang’s work on synthetic peptide-based immunotherapeutics, vaccines, and diagnostics made her the first Asian female recipient of the prestigious award.
Recipient of the 2018 Pioneer in Technology Award given by the Brain Mapping Foundation
The Brain Mapping Foundation (BMF) is established for the purpose of facilitating multidisciplinary brain and spinal cord research, and expediting integration of cutting-edge technologies into the field of Neuroscience. Dr. Wang was the 2018 recipient for Pioneer in Technology Award given by the foundation for her cumulative work on the development of high precision endobody vaccines for the treatment of Neurodegenerative Diseases.
Development of UB-612 SARS-CoV-2 Vaccine by UBI Asia supported by Taiwan government under Dr. Chang Yi Wang’s leadership
In early 2020 during the surprising closing of the WuHan city due to the outbreak of SARS-CoV2, Dr. Wang, determined to utilize her expertise accumulated over the decades in designing viral sequence based innovative antibody screening diagnostics and vaccine, led the UBI group of companies once again in our fight against this disastrous COVID 19 global pandemic. She wrote, with the support of her global team, a total of 8 patent applications with the first being filed on Feb 19th 2020, eight scientific/medical manuscripts for publication of preclinical and clinical reports, and over 10,000 pages of documents including CMC (Chemistry, Manufacturing and Controls) and clinical data packages for regulatory filings, from 2020 to 2022 with its first product UBI SARS-CoV-2 ELISA for antibody screening received US FDA PreEUA on March 17th 2020 and US FDA EUA approval on Jan 15th 2021; and a high precision designer vaccine product UB-612, A Multitope Universal Vaccine against SARS-CoV-2 Variants of Concern (VoCs), which is safe and provides broad and long lasting B- and T cell immune responses, soon to receive EUAs from two countries for global use in 2022.
Important contribution of a Multitope Universal Vaccine against SARS-CoV-2 VoCs towards mankind
Composition-innovated new vaccines against COVID that can better protect against infection of any degree have been strongly advocated. The currently authorized vaccines from November 2021 to 2022 are based on Spike (S) only without incorporation of SARS-CoV-2’s non-spike structure proteins of envelope (E), membrane (M) and nucleocapsid (N), the regions critically involved in the host cell interferon response and T-cell memory. Viral mutations are also known to occur in E, M and N proteins, which are beyond recognition by these currently authorized vaccines.
The booster-enhanced broadly-neutralizing and durable antibodies along with robust T-cell immunity by UB-612, a multitope vaccine which contains S1-RBD-sFc fusion protein enriched with five rationally-designed promiscuous peptides representing conserved Th and CTL epitopes on the Sarbecovirus N, M and S2 proteins across all VoCs allows not only for control of Omicrons or ever-emergent new strains, but also provides another subunit vaccine platform to fend of other infectious viral agents for previously unfinished wars against HIV and Hepatitis B.
Personal life
Dr. Wang divides her time between the United States and Taiwan, actively engaged in R&D and business development activities in biomedical applications. Her husband, Nean Hu , devotes his time to UBI’s subsidiaries in Shanghai, China. She has one daughter, Mei Mei Hu, JD, who serves as CEO of Vaxxinity (VAXX).
A Commemoration of Chang Yi Wang’s Mentors
Robert B. Merrifield
In 1974, Chang Yi, already an astute organic chemist as a result of her undergraduate training at National Taiwan University, joined Dr. Merrifield’s laboratory at Rockefeller University as a first-year Ph.D. student, learning the many facets of solid-phase peptide chemistry. Dr. Merrifield won the Nobel Prize in Chemistry in 1984 for his pioneering work in solid-phase peptide synthesis. Chang Yi’s use of this synthetic tool for some of her inventions in immunological applications in diagnostics, vaccines and immunotherapeutics began in the mid ‘80s.
Henry G. Kunkel
Dr. Kunkel, often referred to as “the father of immunopathology” was Chang Yi’s Ph.D. dissertation advisor from 1975 to 1979 at Rockefeller University. He trained Chang Yi as an investigator, teaching her how to master a few simple technologies and apply them to the most important subjects, and how an inquisitive mind can discover intriguing findings in an ignored corner that few can fathom.
Gerald M. Edelman
Dr. Edelman, an American biologist who received his Ph.D. training at Dr. Kunkel’s laboratory, shared the 1972 Nobel Prize in Physiology or Medicine for work with Rodney R. Porter on the immune system. Specifically, the Nobel Prize was given for his discovery of the structure of antibody molecules. Dr. Edelman and his laboratory colleagues taught immunology and biochemistry classes at Rockefeller University and were instrumental in leading Chang Yi to the most exciting, yet then still primitive, field of immunology.
Ralph M. Steinman
Dr. Steinman, a Canadian Immunologist and cell biologist, was one of the recipients of the 2011 Nobel Prize in Physiology or Medicine for his discovery of the dendritic cell and its role in adaptive immunity. He was the first teacher at the Rockefeller University to bring Chang Yi to the intriguing field of cellular immunology at a time when he was describing his EM finding of dendrite-like immune cells later known as the dendritic cells, critical for initiating the immune responses.
Robert A. Good
Dr. Good, regarded as a founder of modern immunology, was an American physician who performed the first successful human bone marrow transplant between persons who were not identical twins. Chang Yi was recruited immediately after receiving her Ph.D. degree as an independent Principal Investigator and Head of Laboratory of Molecular Immunology by Dr. Good, then president of the Sloan Kettering Institute of the Memorial Sloan Kettering Cancer Center (MSKCC) in Manhattan, the world’s largest cancer center. Her work in the early ‘80s used specific monoclonal antibodies to define several critical lymphocyte surface markers (LEU1, LEU3, LEU4, LEU10, LEU13, LEU14 and the idiotypic leukemic T cell marker, also known as the T cell receptor).
Lloyd J. Old
Dr. Old was one of the founders and standard bearers of the field of cancer immunology. Chang Yi’s entry into the tumor immunology and cytokine fields originated from a collaboration with Dr. Old while at the MSKCC by characterizing a tumor necrosis factor defined by Dr. Old’s laboratory in the ‘70s found in mice serum. The cytokine was purified to homogeneity as a 17KD molecule before it was cloned by Cetus in 1983. Monoclonal antibodies to cytokines including TNF-alpha, funding through a NCI contract, and other tumor-specific antigens—mostly heat-stable glycolipids—were developed in the mid-‘80s by Chang Yi’s laboratory for further clinical applications.
Publications list on SARS vaccine
| No. | Publications | Status |
| 1 | Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus Vaccine | Online MedRxiv. Jun 28, 2023. (https://doi.org/10.1101/2023.06.28.23291948) |
| 2 | Toward a Pan-SARS-CoV-2 vaccine targeting conserved epitopes on spike and non-spike proteins for potent, broad and durable immune responses | PLOS Pathogens. Apr 20, 2023. https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1010870 |
| 3 | A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2 | Emerging Microbes & Infections. Oct 26, 2022. https://doi.org/10.1080/22221751.2022.2140608 |
| 4-1 | A Multitope SARS-CoV-2 Vaccine Provides Long-Lasting B cell and T cell Immunity Against Delta and Omicron Variants (Main) | J Clin Invest. May 16, 2022. https://www.jci.org/articles/view/157707#sd |
| 4-2 | A Multitope SARS-CoV-2 Vaccine Provides Long-Lasting B cell and T cell Immunity Against Delta and Omicron Variants (Supplemental) | J Clin Invest. May 16, 2022. https://www.jci.org/articles/view/157707/sd/1 |
| 5-1 | High Neutralizing Antibody Levels Against SARS-CoV-2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster (Main) | J Infect Dis. Oct 15, 2022. https://doi.org/10.1093/infdis/jiac241 |
| 5-2 | High Neutralizing Antibody Levels Against SARS-CoV-2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster (Supplemental) | J Infect Dis. Oct 15, 2022. https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiac241/6611838?login=false#supplementary-data |
| 6 | UB-612 Multitope Vaccine Targeting Both Spike and Non-Spike Proteins of SARS-CoV-2 Provides Broad and Durable Immune Responses | Online MedRxiv. Aug 30, 2022. (https://www.medrxiv.org/content/10.1101/2022.08.26.22279232v1) |
| 7 | UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern | Online MedRxiv. May 5, 2022. (https://www.medrxiv.org/content/10.1101/2022.04.11.22272364v1) |
| 8 | Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine | Online Research Square. Oct 18, 2021. (https://www.researchsquare.com/article/rs-944205/v1) |
| 9 | Phase 2 Trial Interim Report of a SARS-CoV-2 Multitope Protein-Peptide Vaccine UB-612 | Incorporated into JCI (May, 2022) publication |
| 10 | Phase 1 Trial Report of a SARS-CoV-2 Multitope Protein-Peptide Vaccine UB-612 | Incorporated into JCI (May, 2022) publication |
| 11 | A Novel SARS-CoV-2 RBD-Protein/T Cell Peptide Multitope Vaccine Elicited Neutralizing Antibodies against Multiple Variants of Concerns: T cell Immunity and Protection Against Respiratory Infection in Mice and Non-Human Primates | Online BioRxiv. Oct 7, 2021. (https://www.biorxiv.org/content/10.1101/2020.11.30.399154v2) J Clin Invest. (under review) |
Selected scientific publications list
1. Yu, H. J., Dickson, S. P., Wang, P. N., Chiu, M. J., Huang, C. C., Chang, C. C., Liu, H., Hendrix, S. B. Dodart, J. C., Verma, A., Wang, C. Y., & Cummings, J. (2023). Safety, tolerability, immunogenicity, and efficacy of UB-311 in participants with mild Alzheimer's disease: a randomised, double-blind, placebo-controlled, phase 2a study. EBioMedicine, 94, 104665. https://doi.org/10.1016/j.ebiom.2023.104665
2. Wang, C. Y., Kuo, B. S., Lee, Y. H., Ho, Y. H., Pan, Y. H., Yang, Y. T., … & Peng, W. J. (2023). Targeting Multiple Conserved T-Cell Epitopes for Protection against COVID-19 Moderate-Severe Disease by a Pan-Sarbecovirus Vaccine. medRxiv. https://doi.org/10.1101/2023.06.28.23291948
3. Wang, C. Y., Peng, W. J., Kuo, B. S., Ho, Y. H., Wang, M. S., Yang, Y. T., … & Hwang, K. P. (2023). Toward a pan-SARS-cov-2 vaccine targeting conserved epitopes on Spike and non-spike proteins for potent, broad and durable immune responses. PLOS Pathogens, 19(4). https://doi.org/10.1371/journal.ppat.1010870
4. Wang, S., Wang, C. Y., Kuo, H. K., Peng, W. J., Huang, J. H., Kuo, B. S., … & Guirakhoo, F. (2022). A Novel RBD-Protein/Peptide Vaccine Elicits Broadly Neutralizing Antibodies and Protects Mice and Macaques against SARS-CoV-2. Emerging microbes & infections, 1–22. Advance online publication. https://doi.org/10.1080/22221751.2022.2140608
5. Wang, C. Y., Hwang, K. P., Kuo, H. K., Peng, W. J., Shen, Y. H., Kuo, B. S., ... & Monath, T. P. (2022). A multitope SARS-COV-2 vaccine provides long-lasting B cell and T cell immunity against Delta and Omicron variants. The Journal of Clinical Investigation, 132(10), e157707. https://www.jci.org/articles/view/157707
6. Guirakhoo, F., Wang, S., Wang, C. Y., Kuo, H. K., Peng, W. J., Liu, H., Wang, L., Johnson, M., Hunt, A., Hu, M. M., Monath, T. P., Rumyantsev, A., & Goldblatt, D. (2022). High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. The Journal of infectious diseases, 226(8), 1401–1406. https://doi.org/10.1093/infdis/jiac241
7. Wang, C. Y., Hwang, K. P., Kuo, H. K., Kuo, B. S., Liu, H., Hou, K. L., ... & Peng, W. J. (2022). UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern. medRxiv. https://www.medrxiv.org/content/10.1101/2022.04.11.22272364v1
8. Kuo, B. S., Li, C. H., Chen, J. B., Shiung, Y. Y., Chu, C. Y., Lee, C. H., ... & Wang, C. Y. (2022) IgE Neutralizing UB-221 mAb, distinct from omalizumab and ligelizumab, exhibits CD23-mediated IgE-downregulation and relieves urticaria symptoms. The Journal of Clinical Investigation. https://www.jci.org/articles/view/157765
9. Nimmo, J. T., Smith, H., Wang, C. Y., Teeling, J. L., Nicoll, J. A., Verma, A., ... & Carare, R. O. (2022). Immunisation with UB-312 in the Thy1SNCA mouse prevents motor performance deficits and oligomeric α-synuclein accumulation in the brain and gut. Acta neuropathologica, 143(1), 55-73. https://link.springer.com/article/10.1007/s00401-021-02381-5
10. Hwang, K. P., Wang, C. Y., Huang, C. T., Lee, Y. J., Liu, M. C., Yang, Y. C., ... & Monath, T. P. Phase 2 Trial Interim Report of a SARS-CoV-2 Multitope Protein-Peptide Vaccine UB-612. medRxiv. https://www.medrxiv.org/content/10.1101/2022.04.11.22272364v1
11. Hwang, K. P., Wang, C. Y., Kuo, H. K., Peng, W. J., Shen, Y. H., Hou, K. L., ... & Monath, T. P. Phase 1 Trial Report of a SARS-CoV-2 Multitope Protein-Peptide Vaccine UB-612. medRxiv. https://www.medrxiv.org/content/10.1101/2022.04.11.22272364v1
12. Wang, C. Y. (2022). Peptide immunogens targeting calcitonin gene-related peptide (CGRP) and formulations thereof for prevention and treatment of migraine. U.S. Patent Application No. 17/420,002. https://patents.google.com/patent/US20220073582A1/en
13. Wang, C. Y., Lin, F., Chen, J. B., & Shuang, D. I. N. G. (2022). Peptide immunogens targeting interleukin 6 (IL-6) and formulations thereof for immunotherapy of diseases impacted by IL-6 dysregulation. U.S. Patent Application No. 17/419,163. https://patents.google.com/patent/US20220105163A1/en
14. Wang, C. Y. (2022). Artificial Promiscuous T helper cell epitopes that facilitate targeted antibody production with limited T cell inflammatory response. U.S. Patent Application No. 17/053,059. https://patents.google.com/patent/US20220023400A1/en
15. Wang, C. Y. (2022). Treatment and Sustained Virologic Remission of HIV Infection by Antibodies to CD4 in HAART Stabilized Patients. U.S. Patent No. 11,292,839. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US11292839B2/en
16. Yu, H. J., Dickson S., Wang, P. N., Chiu, M. J., Huang, C. C., Chang, C. C., Liu, H., Hendrix S., Dodart J. C., Verma A., Wang, C. Y., Cummings J. (submitted to Lancet for review). Safety, tolerability, immunogenicity, and efficacy of UB-311 in patients with mild Alzheimer’s disease: A randomised, double-blind, placebo-controlled, phase 2a study. Lancet.
17. Wang, C. Y., & Verma, A. (2021). Peptide immunogen constructs directed against dipeptide repeat proteins from C9ORF72. U.S. Patent Application No. 17/282,336. https://patents.google.com/patent/US20210347866A1/en
18. Wang, C. Y., Hwang, K. P., Kuo, H. K., Peng, J., Shen, D., Kuo, B., ... & Monath, T. (2021). Potent Anti-Delta Effect By a Booster Third-Dose of UB-612, a Precision-Designed SARS-CoV-2 Multitope Protein-Peptide Vaccine. Researchsquare. https://www.researchsquare.com/article/rs-944205/v1
19. Wang, C. Y. (2021). Peptide immunogens of IL-31 and formulations thereof for the treatment and/or prevention of atopic dermatitis. U.S. Patent Application No. 16/771,948. https://patents.google.com/patent/US20210079054A1/en
20. Wang, C. Y. (2021). Tau peptide immunogen constructs. U.S. Patent Application No. 16/759,584. https://patents.google.com/patent/US20210101948A1/en
21. Nimmo, J. T., Verma, A., Dodart, J. C., Wang, C. Y., Savistchenko, J., Melki, R., ... & Nicoll, J. A. (2020). Novel antibodies detect additional α-synuclein pathology in synucleinopathies: potential development for immunotherapy. Alzheimer's Research & Therapy, 12(1), 1-16. https://link.springer.com/article/10.1186/s13195-020-00727-x
22. Guirakhoo, F., Kuo, L., Peng, J., Huang, J. H., Kuo, B., Lin, F., ... & Wang, C. Y. (2020). A novel sars-cov-2 multitope protein/peptide vaccine candidate is highly immunogenic and prevents lung infection in an adeno associated virus human angiotensin-converting enzyme 2 (aav hace2) mouse model. BioRxiv. https://www.biorxiv.org/content/10.1101/2020.11.30.399154v2.full
23. Wang, C. Y., & Peng, W. J. (2020). Immunogenic LHRH composition and use thereof in pigs. U.S. Patent Application No. 16/686,672. https://patents.google.com/patent/US20200069781A1/en
24. Wang, C. Y., Wong, W. W., Tsai, H. C., Chen, Y. H., Kuo, B. S., Lynn, S., ... & Liao, M. J. (2019). Effect of anti-CD4 antibody UB-421 on HIV-1 rebound after treatment interruption. New England Journal of Medicine, 380(16), 1535-1545. https://www.nejm.org/doi/full/10.1056/NEJMoa1802264
25. Verma A., Yu, H. J., Chen, H. C., Wang, C. Y. (2019). Active Anti-Amyloid Immunotherapy with UB-311 Vaccine: Update on design and baseline data of a Phase IIa, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Parallel-Group, Multicenter Study. Journal of Prevention of Alzheimer Disease.
26. Wang, C. Y. (2019). Synthetic peptide-based emergency vaccine against foot and mouth disease (FMD). U.S. Patent No. 10,420,832. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US10420832B2/en
27. Wang, C. Y. (2019). Synthetic Peptide-Based Marker Vaccine and Diagnostic System for Effective Control of Porcine Reproductive and Respiratory Syndrome (PRRS). U.S. Patent No. 10,300,123. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US10300123B2/en
28. Wang, C. Y. (2018). Artificial promiscuous T helper cell epitopes as immune stimulators for synthetic peptide immunogens. U.S. Patent Application No. 62/782,253. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2020132275
29. Wang, C. Y., Lin, F., Chen, J. B. (2018, 2017). Peptide immunogens and formulations thereof targeting membrane-bound IgE for treatment of IgE mediated allergic diseases. TW Patent Application 107147187, WO Application No. PCT/US17/069174. https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2019133024
30. Wang, C. Y. (2018, 2018). Peptide immunogens from the C-Terminal end of alpha-synuclein protein and formulations thereof for treatment of synucleinopathies. TW Patent Application 107120762, WO Application No. PCT/US2018/037938. https://patents.google.com/patent/WO2018232369A1/fi%20US4325121.pdf
31. Wang, C. Y., & Peng, W. J. (2018). Designer Peptide-based PCV2 Vaccine. U.S. Patent No. 9,932,372. Washington, DC: U.S. Patent and Trademark Office. https://patents.google.com/patent/US9932372B2/en
32. Wang, C. Y., Wang, P. N., Chiu, M. J., Finstad, C. L., Lin, F., Lynn, S., ... & Frohna, P. A. (2017). UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 3(2), 262-272. https://www.sciencedirect.com/science/article/pii/S2352873717300227
33. Chen, H. C., Wang, P. N., Chiu, M. J., Huang, C. C., Chang, C. C., Yen, T. C., Lin, K. J., Seibyl J., Hesterman J., Wang, C. Y., Verma A. (2017). Low PET screen failure rate in the UB-311 phase 2A study enriched for ApoE4 carriers with mild cognitive deficit. Poster session presented (November 2017) at Clinical Trials of Alzheimer’s Disease, Boston, MA.
34. Verma A., Maruff P., Schembri A., Wang, P. N., Chiu, M. J., Huang, C. C., ... & Wang, C. Y. (2017). B-311 active vaccine generates titers specific for Aβ oligomers and fibrils without evidence of ARIA-E or encephalopathy in a completed Phase 1 and an ongoing Phase 2a study in Alzheimer’s disease. Poster session presented (November 2017) at Clinical Trials of Alzheimer’s Disease, Boston, MA.
35. Wang, C. Y., Wong, W. W., Tsai, H. C., Chen, Y. H., Liao, M. J., Lynn, S. (2017). Poster Abstract 450LB: A Phase 2 Open-Label Trial of Antibody UB-421 Monotherapy as a Substitute for HAART. Presented at the Annual Conference on Retroviruses and Opportunistic Infections (CROI), February 13-16, 2017, Seattle, WA.
36. Wang, C. Y. (2016, 2016, 2016). Immunoglobulin fusion proteins and use thereof. U.S. Patent No. 15/002,396, TW Patent Application 105117815, WO Application No. PCT/US16/039615.
37. Wang, C. Y. (2016). Peptide vaccine for prevention and immunotherapy of dementia of the Alzheimer’s type. U.S. Patent Application No. 14/824,075. https://patents.google.com/patent/US20160068581A1/en
38. Wang, C. Y., Finstad, C. L., Walfield, A. M., Sia, C., Sokoll, K. K., Chang, T. Y., ... & Windisch, M. (2007). Site-specific UBITh® amyloid-β vaccine for immunotherapy of Alzheimer's disease. Vaccine, 25(16), 3041-3052. https://reurl.cc/VD00Ky
39. Wang, C. Y., & Walfield, A. M. (2005). Site-specific peptide vaccines for immunotherapy and immunization against chronic diseases, cancer, infectious diseases, and for veterinary applications. Vaccine, 23(17-18), 2049-2056. https://reurl.cc/anZe0Z
40. Hsueh, P. R., Kao, C. L., Lee, C. N., Chen, L. K., Ho, M. S., Sia, C., ... & Wang, C. Y. (2004). Highly Specific Severe Acute Respiratory Syndrome Antibody Test for Serosurveillance. Emerging Infectious Diseases, 10, 1558-1562.
41. Wang, C. Y., Lynn, S., Jong, M. H., Lin, Y. L., Chang, T. Y., Walfield, A., ... & Sia, C. (2004). Full Protection in Pigs against FMDV Challenge following Single Dose of Synthetic Emergency FMD Vaccine. Report of the Session of the FAO Research Group of the Standing Technical Committee of the European Commission for the Control of Foot‐and‐Mouth Disease, Crete, Greece, 12–15 October, 365-375. https://www.fao.org/ag/AGAinfo/commissions/docs/research_group/greece04/App58.pdf
42. Finstad, C. L., Wang, C. Y., Kowalski, J., Zhang, M., Li, M. L., Li, X. M., ... & Zamb, T. J. (2004). Synthetic luteinizing hormone releasing hormone (LHRH) vaccine for effective androgen deprivation and its application to prostate cancer immunotherapy. Vaccine, 22(9-10), 1300-1313. https://reurl.cc/XjZAEE
43. Wang, C. Y., Walfield, A. M., Fang, X., Hammerberg, B., Ye, J., Li, M. L., ... & MacGlashan, D. W. (2003). Synthetic IgE peptide vaccine for immunotherapy of allergy. Vaccine, 21(15), 1580-1590. https://reurl.cc/d21QLD
44. Wang, C. Y., Shen, M., Tam, G., De Fang, X., Ye, J., Shen, F., ... & Hanson, C. V. (2002). Synthetic AIDS vaccine by targeting HIV receptor. Vaccine, 21(1-2), 89-97. https://reurl.cc/55DKvV
45. Wang, C. Y., Chang, T. Y., Walfield, A. M., Ye, J., Shen, M., Chen, S. P., ... & Brown, F. (2002). Effective synthetic peptide vaccine for foot-and-mouth disease in swine. Vaccine, 20(19-20), 2603-2610. https://reurl.cc/g2eR6b
46. Wang, C. Y., Chang, T. Y., Walfield, A. M., Ye, J., Shen, M., Zhang, M. L., ... & Brown, F. (2001). Synthetic peptide-based vaccine and diagnostic system for effective control of FMD. Biologicals, 29(3-4), 221-228. https://www.sciencedirect.com/science/article/pii/S1045105601903021
47. Wang, C. Y., Sawyer, L. S., Murthy, K. K., Fang, X., Walfield, A. M., Ye, J., ... & Hanson, C. V. (1999). Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex. Proceedings of the National Academy of Sciences, 96(18), 10367-10372. https://www.pnas.org/content/96/18/10367.short
48. Shen, F., Chen, P. D., Walfield, A. M., Ye, J., House, J., Brown, F., & Wang, C. Y. (1999). Differentiation of convalescent animals from those vaccinated against foot-and-mouth disease by a peptide ELISA. Vaccine, 17(23-24), 3039-3049. https://reurl.cc/RrLYkg
49. Singh, M., Li, X. M., Wang, H., McGee, J. P., Zamb, T., Koff, W., Wang, C. Y., O'hagan, D. T. (1998). Controlled release microparticles as a single dose diphtheria toxoid vaccine: immunogenicity in small animal models. Vaccine, 16(4), 346-352. https://www.sciencedirect.com/science/article/pii/S0264410X97809127
50. Singh, M., Hioe, C., Qiu, H., Li, X. M., Wang, C. Y., Koff, W., ... & Nixon, D. F. (1997). CTL induction using synthetic peptides delivered in emulsions—critical role of the formulation procedure. Vaccine, 15(16), 1773-1778. https://www.sciencedirect.com/science/article/pii/S0264410X97001096
51. Li, D., Forrest, B. D., Li, Z., Xue, P., Hanson, C. V., Duan, S., Cheng, H. H., Li, M. L., Wang, C. Y. & Koff, W. C. (1997). International clinical trials of HIV vaccines: II. Phase I trial of an HIV-1 synthetic peptide vaccine evaluating an accelerated immunization schedule in Yunnan, China. Asian Pacific Journal of Allergy and Immunology, 15, 105-114. https://reurl.cc/9G6DLx
52. Phanuphak, P., Teeratakulpixam, S., Sarangbin, S., Nookhai, S., Ubolyam, S., Sirivichayakul, S., Leesavan A., Forrest B. D., Hanson C. V., Li, M. L., Wang, C. Y. & Koff, W. C. (1997). International clinical trials of HIV vaccines: I. Phase I trial of an HIV-1 synthetic peptide vaccine in Bangkok, Thailand. Asian Pacific Journal of Allergy and Immunology, 15(1), 41. https://reurl.cc/vdpQb1
53. SinghX, M., McGee, J. P., Li, X. M., Koff, W., Zamb, T., Wang, C. Y., & O’Hagan, D. T. (1997). Biodegradable microparticles with an entrapped branched octameric peptide as a controlled-release HIV-1 vaccine. Journal of pharmaceutical sciences, 86(11), 1229-1233. https://www.sciencedirect.com/science/article/pii/S0022354915504218
54. Singh, M., Li, X. M., McGee, J. P., Zamb, T., Koff, W., Wang, C. Y., & O'hagan, D. T. (1997). Controlled release microparticles as a single dose hepatitis B vaccine: evaluation of immunogenicity in mice. Vaccine, 15(5), 475-481. https://www.sciencedirect.com/science/article/pii/S0264410X97002259
55. Singh, M., Li, X. M., Wang, H., McGee, J. P., Zamb, T., Koff, W., Wang, C. Y. & O'Hagan, D. T. (1997). Immunogenicity and protection in small-animal models with controlled-release tetanus toxoid microparticles as a single-dose vaccine. Infection and immunity, 65(5), 1716-1721. https://journals.asm.org/doi/abs/10.1128/iai.65.5.1716-1721.1997
56. Nixon, D. F., Hioe, C., Bian, Z., Kuebler, P., Li, M. L., Qiu, H., Li, X. M., Singh M., Richardson J., McGee P., Zamb T., Koff W., Wang, C. Y. & O'Hagan, D. (1996). Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine, 14(16), 1523-1530. https://www.sciencedirect.com/science/article/pii/S0264410X96000990
57. Hioe, C. E., Qiu, H., Chend, P. D., Bian, Z., Li, M. L., Li, J., Singh M., Kuebler P., McGee P.,O’Hagan D., Zamb T., Koff W., Allsopp C., Wang, C. Y. & Nixon, D. F. (1996). Comparison of adjuvant formulations for cytotoxic T cell induction using synthetic peptides. Vaccine, 14(5), 412-418. https://www.sciencedirect.com/science/article/pii/0264410X95001913
58. Quiroga, J. A., Van Binsbergen, J., Wang, C. Y., Pardo, M., Navas, S., Trines, C., ... & Carreno, V. (1995). Immunoglobulin M antibody to hepatitis C virus core antigen: correlations with viral replication, histological activity, and liver disease outcome. Hepatology, 22(6), 1635-1640. https://www.sciencedirect.com/science/article/pii/0270913995901841
59. Prince, A. M., Brotman, B., Inchauspé, G., Pascual, D., Nasoff, M., Hosein, B., & Wang, C. Y. (1993). Patterns and prevalence of hepatitis C virus infection in posttransfusion non-A, non-B hepatitis. Journal of Infectious Diseases, 167(6), 1296-1301. https://academic.oup.com/jid/article-abstract/167/6/1296/953808
60. Sheu, J. C., Wang, J. T., Wang, T. H., Wang, C. Y., Yang, P. M., Huang, G. T., ... & Chen, D. S. (1993). Prevalence of hepatitis C viral infection in a community in Taiwan: Detection by synthetic peptide-based assay and polymerase chain reaction. Journal of hepatology, 17(2), 192-198. https://www.sciencedirect.com/science/article/pii/S0168827805800376
61. Wang, C. Y., Looney, D. J., Li, M. L., Walfield, A. M., Ye, J., Hosein, B., ... & Wong-Staal, F. (1991). Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. Science, 254(5029), 285-288. https://www.science.org/doi/abs/10.1126/science.1925584
62. Magrin, S., Pinzello, G., Craxi, A., Almasio, P., Pagliaro, L., Hosein, B., Fang, X., Wang, C. Y., ... & Kobayashi, K. (1992). Anti-HCV, anti-GOR, and autoimmunity. The Lancet, 339(8797), 871-872. https://www.thelancet.com/journals/lancet/article/PII0140-6736(92)90315-T/fulltext
63. Hosein, B., Fang, C. T., Popovsky, M. A., Ye, J., Zhang, M., & Wang, C. Y. (1991). Improved serodiagnosis of hepatitis C virus infection with synthetic peptide antigen from capsid protein. Proceedings of the National Academy of Sciences, 88(9), 3647-3651. https://www.pnas.org/content/88/9/3647.short
64. Lal, R. B., Heneine, W., Rudolph, D. L., Present, W. B., Hofhienz, D., Hartley, T. M., ... & Kaplan, J. E. (1991). Synthetic peptide-based immunoassays for distinguishing between human T-cell lymphotropic virus type I and type II infections in seropositive individuals. Journal of clinical microbiology, 29(10), 2253-2258.
65. Hosein B., Present W., Wang, C. Y., & Fang C. T. (1990). Synthetic peptide-based EIAs to distinguish HTLV-I from HTLV-II infection. Transfusion, 30S, 513.
66. Kao, H. T., Gregersen, P. K., Tang, J. C., Takahashi, T., Wang, C. Y., & Silver, J. (1989). Molecular analysis of the HLA class II genes in two DRw6-related haplotypes, DRw13 DQw1 and DRw14 DQw3. The Journal of Immunology, 142(5), 1743-1747. https://www.jimmunol.org/content/142/5/1743.short?casa_token=lnFoW9n62uIAAAAA:Y-o6chyjLj1kZBGN7EKgmAbZRvnhPfnr790v4Pifx-H4mi8U1Ro2KWe4c1FgeJQVo-HxtIiMGN476aQ
67. Sung, S. S., Bjorndahl, J. M., Wang, C. Y., Kao, H. T., & Fu, S. M. (1988). Production of tumor necrosis factor/cachectin by human T cell lines and peripheral blood T lymphocytes stimulated by phorbol myristate acetate and anti-CD3 antibody. The Journal of experimental medicine, 167(3), 937-953. https://rupress.org/jem/article-abstract/167/3/937/24039
68. Sung, S. S., Jung, L. K., Walters, J. A., Chen, W., Wang, C. Y., & Fu, S. M. (1988). Production of tumor necrosis factor/cachectin by human B cell lines and tonsillar B cells. The Journal of experimental medicine, 168(5), 1539-1551. https://rupress.org/jem/article-abstract/168/5/1539/49932
69. Wang, C. Y. (1988). Synthetic-peptide-based immunodiagnosis of retrovirus infections: current status and future prospects. Advances in Biotechnological Processes, 10, 131-148. https://europepmc.org/article/med/2848540
70. Shimazaki, C., Wisniewski, D., Scheinberg, D. A., Atzpodien, J., Strife, A., Gulati, S., Fried J.,Wisniewolski R., Wang, C. Y., & Clarkson, B. D. (1988). Elimination of myeloma cells from bone marrow by using monoclonal antibodies and magnetic immunobeads. https://ashpublications.org/blood/article-abstract/72/4/1248/166410
71. Gottlieb, A. B., Lifshitz, B., Fu, S. M., Staiano-Coico, L., Wang, C. Y., & Carter, D. M. (1986). Expression of HLA-DR molecules by keratinocytes, and presence of Langerhans cells in the dermal infiltrate of active psoriatic plaques. The Journal of experimental medicine, 164(4), 1013-1028. https://rupress.org/jem/article-abstract/164/4/1013/23786
72. Gregersen, P. K., Shen, M., Song, Q. L., Merryman, P., Degar, S., Seki, T., Maccari J., Goldberg D., Murphy H., Schwenzer J., Wang, C. Y., ... & Silver, J. (1986). Molecular diversity of HLA-DR4 haplotypes. Proceedings of the National Academy of Sciences, 83(8), 2642-2646. https://www.pnas.org/doi/abs/10.1073/pnas.83.8.2642
73. Kan, E. A. R., Wright, S. D., Welte, K., & Wang, C. Y. (1986). Fc receptors on monocytes cause OKT3-treated lymphocytes to internalize T3 and to secrete IL-2. Cellular Immunology, 98(1), 181-187. https://www.sciencedirect.com/science/article/pii/0008874986902789
74. Bushkin, Y., Posnett, D. N., Pernis, B., & Wang, C. Y. (1986). A new HLA-linked T cell membrane molecule, related to the beta chain of the clonotypic receptor, is associated with T3. The Journal of experimental medicine, 164(2), 458-473. https://rupress.org/jem/article-abstract/164/2/458/49447
75. Posnett, D. N., Wang, C. Y., & Friedman, S. M. (1986). Inherited polymorphism of the human T-cell antigen receptor detected by a monoclonal antibody. Proceedings of the National Academy of Sciences, 83(20), 7888-7892. https://www.pnas.org/content/83/20/7888.short
76. Tse, D. B., Al-Haideri, M., Pernis, B., Cantor, C. R., & Wang, C. Y. (1986). Intracellular accumulation of T-cell receptor complex molecules in a human T-cell line. Science, 234(4777), 748-751. https://www.science.org/doi/abs/10.1126/science.3490690
77. Wang, J. J., Steel, S., Wisniewolski, R., & Wang, C. Y. (1986). Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein. Proceedings of the National Academy of Sciences, 83(16), 6159-6163. https://www.pnas.org/content/83/16/6159.short
78. Wang, C. Y., Bushkin, Y. U. R. I., Pica, R. A. Y. M. O. N. D., Lane, C. A. R. Y. L., McGRATH, H. E. L. E. N., & Posnett, D. N. (1986). Stimulation and expansion of a human T-cell subpopulation by a monoclonal antibody to T-cell receptor molecule. Hybridoma, 5(3), 179-190. https://www.liebertpub.com/doi/abs/10.1089/hyb.1986.5.179?casa_token=GMiAEbbX0JEAAAAA:ZCJBRySip2iADw6WLpwRfjoEzk0S3BnEpkNEsoKlxIEyIJzbBX2Rj6wyfW0SgN8ZVszZQZQMkC1MDg
79. Schwalting, R., Stein, H., & Wang, C. Y. (1983). The monoclonal antibodies S-HCL1 (Leu-14) and S-HCL-1 (Leu-M5) allow the diagnosis of hairy cell leukemia. Blood, 65, 974.
80. Bushkin, Y., Chorney, M. J., Diamante, E., Lane, C., Fu, S. M., & Wang, C. Y. (1985). Biochemical characterization of a p43, 12 complex: comparison with human and murine class I molecules. Molecular immunology, 22(6), 695-703. https://www.sciencedirect.com/science/article/pii/0161589085901002
81. Schwarting, R., Welte, K., Chiorazzi, N., Ralph, P., Lane, C. L., Long, C., & Wang, C. Y. (1985). Biochemical characterization and purification of human B cell stimulatory factor (BSF). European journal of immunology, 15(6), 632-637. https://onlinelibrary.wiley.com/doi/abs/10.1002/eji.1830150619?casa_token=5DbNZQZkIwQAAAAA:69ytWpjvA-SgMzKGQzUprTeHBwPXolnIjIiufHZOnAI-927to31LUpMVMcak0GQVZ_95eDNXpxgbHaQ
82. Wang, C. Y., Bushkin, Y. U. R. I., Chen, P. D., Platsoucas, C. D., & Long, C. E. D. R. I. C. (1984). Preparation and characterization of monoclonal antibodies directed at epitopes of human IFN-γ. Hybridoma, 3(4), 321-332. https://www.liebertpub.com/doi/abs/10.1089/hyb.1984.3.321?casa_token=n87XEkJ-ITkAAAAA:H25KQYek3lc0Otj0g-I7jCxp2oQ9jxPPaduXLTu4r5nthXPXmSKsh5n3AQGwtC_zYT9LHbkZoXq-iBs
83. Bushkin, Y., Chorney, M. J., Diamante, E., Fu, S. M., & Wang, C. Y. (1984). Biochemical characterization of the human T6 antigen: A comparison between T6 and murine TL. Molecular immunology, 21(10), 821-829. https://www.sciencedirect.com/science/article/pii/0161589084901354
84. Posnett, D. N., Bigler, R. D., Bushkin, Y., Fisher, D. E., Wang, C. Y., Mayer, L. F., ... & Kunkel, H. G. (1984). T cell antiidiotypic antibodies reveal differences between two human leukemias. The Journal of experimental medicine, 160(2), 494-505. https://rupress.org/jem/article-abstract/160/2/494/23438
85. Posnett, D. N., Wang, C. Y., Chiorazzi, N., Crow, M. K., & Kunkel, H. G. (1984). An antigen characteristic of hairy cell leukemia cells is expressed on certain activated B cells. The Journal of Immunology, 133(3), 1635-1640. https://www.jimmunol.org/content/133/3/1635.short?casa_token=K-VBPixmXg4AAAAA:XOIHpFDuv7P3aIBUJR1J19FYZuUZ0CIOH0JlxcP4nv5E3UDmZ8osC1gb4mji93nHp7Ae_vtItQA4dxo
86. Peng, R., Al-Katib, A., Knowles, D. 2., Lu, L., Broxmeyer, H., Tolidjian, B., ... & Wang, C. Y. (1984). Preparation and characterization of monoclonal antibodies recognizing two distinct differentiation antigens (Pro-Im1, Pro-Im2) on early hematopoietic cells. Blood, 64, 1169. https://ashpublications.org/blood/article-abstract/64/6/1169/163864
87. Kan, E. R., Platzer, E., Welte, K., & Wang, C. Y. (1984). Modulation induction of the T3 antigen by OKT3 antibody is monocyte dependent. The Journal of Immunology, 133(6), 2979-2985. https://www.jimmunol.org/content/133/6/2979.short?casa_token=biT6loPdQsEAAAAA:y5CH59m13O9b08-AN83BagsHVKDNJ_8Od6ZEYnJL2qmq0cO5UWAIDcKlsgJJNhhrfWno3faUhGI0aDQ
88. Wang, C. Y., Azzo, W., Al-Katib, A., Chiorazzi, N., & Knowles, D. M. (1984). Preparation and characterization of monoclonal antibodies recognizing three distinct differentiation antigens (BL1, BL2, BL3) on human B lymphocytes. The Journal of Immunology, 133(2), 684-691. https://www.jimmunol.org/content/133/2/684.short?casa_token=TbbJQKHMvWgAAAAA:xo3au8YhpPdNy9IHyx8lfAHrujM2_5rh4qoBqVPe7SOWL9Uhakd51N-v0Mo15Go51Hd75a1zuB1Q-Vc
89. Wang, C. Y., Al-Katib, A. Y. A. D., Lane, C. L., Koziner, B., & Fu, S. M. (1983). Induction of HLA-DC/DS (LEU 10) antigen expression by human precursor B cell lines. The Journal of experimental medicine, 158(5), 1757-1762. https://rupress.org/jem/article-abstract/158/5/1757/57217
90. Kan, E. A., Wang, C. Y., Wang, L. C., & Evans, R. L. (1983). Noncovalently bonded subunits of 22 and 28 kd are rapidly internalized by T cells reacted with anti-Leu-4 antibody. The Journal of Immunology, 131(2), 536-539. https://www.jimmunol.org/content/131/2/536.short?casa_token=yBv7xpKF-VIAAAAA:GRHvNeVVz9CQ8o0hYPnObFfkOt6W6Q4q15GnOGt77dA2TcGhfvDL2MJH3_RfvkXmP_xgnGinyXGGroM
91. Bigler, R. D., Fisher, D. E., Wang, C. Y., Rinnooy Kan, E. A., & Kunkel, H. G. (1983). Idiotype-like molecules on cells of a human T cell leukemia. The Journal of experimental medicine, 158(3), 1000-1005. https://rupress.org/jem/article-abstract/158/3/1000/23038
92. Welte, K., Platzer, E., Wang, C. Y., Kan, E. R., Moore, M. A., & Mertelsmann, R. (1983). OKT8 antibody inhibits OKT3-induced IL 2 production and proliferation in OKT8+ cells. The Journal of Immunology, 131(5), 2356-2361. https://www.jimmunol.org/content/131/5/2356.short?casa_token=MpJUW9U6c5EAAAAA:Ov9Pi3j1iQQlNhBkvvUUdLX98VA4vgpwEzK3h5sRRgZC1MzQBXgSdhawDFiR2MCaKcl9vnhW3X04bCY
93. Knowles, D. 2., Tolidjian, B., Marboe, C. C., Halper, J. P., Azzo, W., & Wang, C. Y. (1983). A new human B-lymphocyte surface antigen (BL 2) detectable by a hybridoma monoclonal antibody: distribution on benign and malignant lymphoid cells. Blood, 62, 191. https://ashpublications.org/blood/article-abstract/62/1/191/163647
94. Venuta, S., Mertelsmann, R., Welte, K., Feldman, S. P., Wang, C. Y., & Moore, M. A. (1983). Production and regulation of interleukin-2 in human lymphoblastic leukemias studied with T-cell monoclonal antibodies. Blood, 61, 781. https://ashpublications.org/blood/article-abstract/61/4/781/163386
95. Miki, Y., Kishi, H., Muraguchi, A., Maruyama, S., Kishimoto, S., Yamamura, Y., Wang, C. Y., & Kishimoto, T. (1982). Induction of IgG production in a human monoclonal B lymphoblastoid cell line by a B cell-specific monoclonal antibody. The Journal of Immunology, 129(5), 1921-1925. https://www.jimmunol.org/content/129/5/1921.short?casa_token=o0mRs8m8omMAAAAA:30b6kcvohZ0Nt4K6ObynxnifXfQNGuXjXwsAlDqBB_GFtD9QT3NcBPoXXh3uBy_ueOe-v2DtiBwUKrE
96. Welte, K., Wang, C. Y., Mertelsmann, R., Venuta, S., Feldman, S. P., & Moore, M. A. (1982). Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity. The Journal of experimental medicine, 156(2), 454-464. https://rupress.org/jem/article-abstract/156/2/454/23120
97. Shin, H. S., Wang, C. Y., & Choi, Y. S. (1981). Activation of autologous reactive helper T lymphocytes for differentiation of human B lymphocytes. The Journal of Immunology, 126(6), 2485-2489. https://www.jimmunol.org/content/126/6/2485.short?casa_token=Ex9yEinVtQUAAAAA:mKWJ0WXo1E8FiSwCdvbyH3jYrnN-0O9slopxxHqYVA6V3-S3eudJBvW4JGTyJzgCndsHe9Dgw9Kc8GY
98. Wang, C. Y., Good, R. A., Ammirati, P., Dymbort, G. I. N. Y., & Evans, R. L. (1980). Identification of a p69, 71 complex expressed on human T cells sharing determinants with B-type chronic lymphatic leukemic cells. The Journal of experimental medicine, 151(6), 1539-1544. https://rupress.org/jem/article-abstract/151/6/1539/48692
99. Halper, J. P., Knowles II, D. M., & Wang, C. Y. (1980). Ia antigen expression by human malignant lymphomas: Correlation with conventional lymphoid markers. Blood, 55(3), 373-382. https://www.sciencedirect.com/science/article/pii/S0006497120691479
100. Gottlieb, A. B., Fu, S. M., David, T. Y., Wang, C. Y., Halper, J. P., & Kunkel, H. G. (1979). The nature of the stimulatory cell in human allogeneic and autologous MLC reactions; role of isolated IgM-bearing B cells. The Journal of Immunology, 123(4), 1497-1503. https://www.jimmunol.org/content/123/4/1497.short?casa_token=7ZSzLe61K4YAAAAA:ZYG9qgpRLe5s2tJwdQzPUjTvl-a7ln_pmFjHdunsF0xMPCChUrmrlhnv5K4_tFBJkRf6oHy5Syz2ztg
101. Wang, C. Y. (1979). Structural and Functional Characterication of Surface Antigens on Human B Lymphocytes (Doctoral dissertation, Rockefeller University).
102. Wang, C. Y., Fu, S. M., & Kunkel, H. G. (1979). Isolation and immunological characterization of a major surface glycoprotein (gp54) preferentially expressed on certain human B cells. The Journal of experimental medicine, 149(6), 1424-1437. https://rupress.org/jem/article-abstract/149/6/1424/22530
103. Fu, S. M., Chiorazzi, N., Wang, C. Y., Montrazeri, G., Kunkel, H. G., Ko, H. S., & Gottlieb, A. B. (1978). Ia-bearing T lymphocytes in man. Their identification and role in the generation of allogeneic helper activity. The Journal of experimental medicine, 148(5), 1423-1428. https://rupress.org/jem/article-abstract/148/5/1423/22519
104. Winchester, R. J., Wang, C. Y., Gibofsky, A., Kunkel, H. G., Lloyd, K. O., & Old, L. J. (1978). Expression of Ia-like antigens on cultured human malignant melanoma cell lines. Proceedings of the National Academy of Sciences, 75(12), 6235-6239. https://www.pnas.org/content/75/12/6235.short
105. Winchester, R. J., Meyers, P. A., Broxmeyer, H. E., Wang, C. Y., Moore, M. A., & Kunkel, H. G. (1978). Inhibition of human erythropoietic colony formation in culture by treatment with Ia antisera. The Journal of experimental medicine, 148(2), 613-618. https://rupress.org/jem/article-abstract/148/2/613/22382
106. Halper, J., Fu, S. M., Wang, C. Y., Winchester, R., & Kunkel, H. G. (1978). Patterns of expression of human “Ia-like” antigens during the terminal stages of B cell development. The Journal of Immunology, 120(5), 1480-1484. https://www.jimmunol.org/content/120/5/1480.short?casa_token=ZQa0sDeTC4AAAAAA:RypJ532DKv0g19LhRnbpfD9LXSLIHjVCJUVHnNXza63wh0Zw_da1giymwqEnXLVlmS4I5x9i23xO_rM
107. Hoffman, T., Wang, C. Y., Winchester, R. J., Ferrarini, M., & Kunkel, H. G. (1977). Human lymphocytes bearing “Ia-like” antigens; absence in patients with infantile agammaglobulinemia. The Journal of Immunology, 119(4), 1520-1524. https://www.jimmunol.org/content/119/4/1520.short?casa_token=MqM9k3mI4goAAAAA:0drECcwPKaw_13bUDXCArtFuGtoaDng310t1kGrgQMHQAqagvlNyAvXQLEn3KH_et99aRYU4RE9JLCY
108. Winchester, R. J., Ross, G. D., Jarowski, C. I., Wang, C. Y., Halper, J., & Broxmeyer, H. E. (1977). Expression of Ia-like antigen molecules on human granulocytes during early phases of differentiation. Proceedings of the National Academy of Sciences, 74(9), 4012-4016. https://www.pnas.org/content/74/9/4012.short